1881-P: The SGLT2 Inhibitor Dapagliflozin Improves Glucose Control and Enhances Liver Fatty Acid Oxidation and Ketone Body Formation in Insulin Resistant Obese Zucker Rats

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective treatments for improving glucose control and reducing cardiovascular events in patients with T2D. In the present study we examined the metabolic effects of chronic treatment of the SGLT2i dapagliflozin in obese insulin resistant Zucker rats. Three different studies were performed with the aims to assess: 1) liver CoA intermediates, 2) whole-body FA metabolism using a constant...